https://scholars.lib.ntu.edu.tw/handle/123456789/641385
標題: | Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents | 作者: | Hsu, Wei-Fan Lai, Hsueh-Chou Chuang, Po-Heng Su, Wen-Pang Chen, Sheng-Hung Chen, Hung-Yao Wang, Hung-Wei GUAN-TARN HUANG Peng, Cheng-Yuan |
關鍵字: | chronic hepatitis C; direct-acting antiviral agent; hepatocellular carcinoma; liver-related complication; nonalcoholic fatty liver disease fibrosis score | 公開日期: | 九月-2022 | 卷: | 29 | 期: | 9 | 起(迄)頁: | 785 | 來源出版物: | Journal of viral hepatitis | 摘要: | Patients with chronic hepatitis C (CHC) have a higher prevalence of hepatic steatosis and dyslipidaemia than healthy individuals. We analysed noninvasive fibrosis assessments, especially nonalcoholic fatty liver disease (NAFLD)-related noninvasive fibrosis tests, for predicting liver-related complications and hepatocellular carcinoma (HCC) occurrence in patients with CHC. This retrospective study enrolled 590 consecutive patients with CHC having a sustained virologic response (SVR) to direct-acting antiviral agent (DAA) therapy. The NAFLD fibrosis score (NFS) exhibiting the highest value of area under the receiver operating characteristic curve (AUROC) was selected for comparison with the fibrosis-4 index (FIB-4). Of the 590 patients, 188 had metabolic syndrome. A multivariate Cox regression analysis identified total bilirubin at 3 or 6 months after DAA therapy (PW12), NFS at PW12 (hazard ratio [HR]: 2.125, 95% confidence interval [CI]: 1.058-4.267, p = .034) and alpha-fetoprotein (AFP) at PW12 (HR: 1.071, 95% CI: 1.005-1.142, p = .034) as the independent predictors of liver-related complications in all patients. In patients with metabolic syndrome, NFS and AFP values at PW12 were independent predictors of liver-related complications and HCC occurrence. Time-dependent NFS AUROC values at PW12 for 1-, 2- and 3-year liver-related complications were higher than NFS values at baseline in patients with metabolic syndrome. NFS at baseline or PW12 is a more effective predictor of liver-related complications than FIB-4 values in all patients. NFS at PW12 may be a useful predictor of liver-related complications and HCC development in patients with CHC with an SVR to DAA therapy, especially in those with metabolic syndrome. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85131758639&doi=10.1111%2fjvh.13715&origin=inward&txGid=8b7d57dfe686c53d2e3507e7527fcb9f https://scholars.lib.ntu.edu.tw/handle/123456789/641385 |
ISSN: | 13520504 | DOI: | 10.1111/jvh.13715 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。